We are live on
!
Find out more
Aberdeen Group Portfolio holdings
AUM
$61.9B
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
+5.07%
1 Year Est. Return
+29.81%
3 Year Est. Return
+93.17%
5 Year Est. Return
+119.65%
10 Year Est. Return
–
AUM
$64.6B
AUM Growth
+$1.37B
(+2.2%)
Cap. Flow
-$686M
Cap. Flow
% of AUM
-1.06%
Top 10 Holdings %
Top 10 Hldgs %
38.17%
Holding
995
New
43
Increased
362
Reduced
491
Closed
59
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nu Holdings
NU
|
+$36.3M |
| 2 |
SCHW
Charles Schwab
SCHW
|
+$36.1M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$35.6M |
| 4 |
Danaher
DHR
|
+$30.5M |
| 5 |
uniQure
QURE
|
+$28.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$93.5M |
| 2 |
Mercado Libre
MELI
|
+$86M |
| 3 |
Microsoft
MSFT
|
+$62.9M |
| 4 |
Apple
AAPL
|
+$55.6M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$48.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.59% |
| 2 | Healthcare | 13.39% |
| 3 | Consumer Discretionary | 11.41% |
| 4 | Communication Services | 11.25% |
| 5 | Financials | 10.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
176
Cigna
CI
$78.4B
| $60.2M | 0.09% |
218,661
-5,096
| -2% | -$1.43M |
|
177
Freeport-McMoran
FCX
$86.2B
| $59.4M | 0.09% |
1,169,942
-33,910
| -3% | -$1.47M |
|
178
AvalonBay Communities
AVB
$27.5B
| $59M | 0.09% |
325,316
-18,378
| -5% | -$3.33M |
|
179
Omega Healthcare
OHI
$15.3B
| $57.9M | 0.09% |
1,305,221
+89,625
| +7% | +$3.86M |
|
180
ResMed
RMD
$31.1B
| $57.6M | 0.09% |
239,236
-37,737
| -14% | -$9.65M |
|
|
ABVX
181
Abivax
ABVX
$10.4B
| $57.5M | 0.09% |
426,658
-360,759
| -46% | -$39.4M |
|
182
Quanta Services
PWR
$84.2B
| $57.1M | 0.09% |
135,348
-1,568
| -1% | -$689K |
|
183
Motorola Solutions
MSI
$72.1B
| $56.8M | 0.09% |
148,143
-27
| -0% | -$10.9K |
|
184
Travelers Companies
TRV
$81.1B
| $56.6M | 0.09% |
195,089
-4,245
| -2% | -$1.19M |
|
185
Target
TGT
$66.3B
| $56.2M | 0.09% |
574,744
-5,636
| -1% | -$519K |
|
186
HDFC Bank
HDB
$123B
| $55.4M | 0.09% |
1,517,149
+396,336
| +35% | +$14.3M |
|
187
Exelon
EXC
$48.1B
| $55.4M | 0.09% |
1,270,655
-17,129
| -1% | -$782K |
|
188
Keurig Dr Pepper
KDP
$42.8B
| $54.7M | 0.08% |
1,951,437
+107,314
| +6% | +$2.95M |
|
189
Marriott International
MAR
$100B
| $54.4M | 0.08% |
175,442
-1,934
| -1% | -$552K |
|
190
FedEx
FDX
$73B
| $54.2M | 0.08% |
187,552
-8,713
| -4% | -$2.29M |
|
191
Aon
AON
$80.6B
| $54.1M | 0.08% |
153,289
-2,902
| -2% | -$1.01M |
|
192
Eversource Energy
ES
$28.1B
| $53.9M | 0.08% |
800,328
-5,202
| -0.6% | -$365K |
|
193
Hilton Worldwide
HLT
$72.4B
| $53.6M | 0.08% |
186,708
-2,010
| -1% | -$547K |
|
194
Allstate
ALL
$70.6B
| $53.6M | 0.08% |
257,526
+5,375
| +2% | +$1.1M |
|
195
TransDigm Group
TDG
$70.7B
| $53.5M | 0.08% |
40,195
-274
| -0.7% | -$359K |
|
196
Cencora
COR
$62B
| $53M | 0.08% |
156,905
-1,659
| -1% | -$566K |
|
197
Alnylam Pharmaceuticals
ALNY
$38.3B
| $52.8M | 0.08% |
132,846
-24,550
| -16% | -$10.9M |
|
198
Consolidated Edison
ED
$41.4B
| $52.3M | 0.08% |
526,918
-2,369
| -0.4% | -$235K |
|
199
Duke Energy
DUK
$101B
| $52.2M | 0.08% |
445,781
+51,501
| +13% | +$6.29M |
|
200
Xylem
XYL
$28.5B
| $51.9M | 0.08% |
381,016
+17,620
| +5% | +$2.53M |
|
Similar funds
Aberdeen Group's Q4 2025 Portfolio in Review
As of Q4 2025, Aberdeen Group held 995 positions worth $64.6B, up 2.2% from $63.2B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Aberdeen Group's Q4 2025 filing shows 43 new, 362 increased, 491 reduced and 59 closed positions. Its largest new stake was Praxis Precision Medicines: 134,992 shares worth $39.8M. The largest sale was Eli Lilly, an estimated $93.5M.
By sector, the portfolio is most concentrated in Technology at 33% of assets, down from 33% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Aberdeen Group's largest Q4 2025 buy was Praxis Precision Medicines: 134,992 shares worth $39.8M.
- Aberdeen Group added most to Nu Holdings in Q4 2025, an estimated $36.3M increase.
- Aberdeen Group's biggest Q4 2025 reduction was Eli Lilly, cutting an estimated $93.5M.
- Aberdeen Group fully exited BioMarin Pharmaceuticals in Q4 2025, selling an estimated $48.9M.
- Aberdeen Group's ten largest holdings make up 38% of its $64.6B portfolio in Q4 2025.
- Aberdeen Group opened 43 new positions and closed 59 in Q4 2025.
- Aberdeen Group's portfolio value rose 2.2% quarter-over-quarter to $64.6B.
Based on Aberdeen Group's 13F filing for Q4 2025, filed 16 Jan 2026.